CN1593558A - Sarcandra extract and its application - Google Patents
Sarcandra extract and its application Download PDFInfo
- Publication number
- CN1593558A CN1593558A CN 200410027691 CN200410027691A CN1593558A CN 1593558 A CN1593558 A CN 1593558A CN 200410027691 CN200410027691 CN 200410027691 CN 200410027691 A CN200410027691 A CN 200410027691A CN 1593558 A CN1593558 A CN 1593558A
- Authority
- CN
- China
- Prior art keywords
- extract
- medicine
- pileae scriptae
- herba pileae
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a Sarcandra extract and its application, which is prepared from the overground portion of plant Sarcandra glabra (Thumb) Nakai through water extraction and ethanol precipitation method, wherein the active extractive is obtained by drying the precipitate, each 100g active extractive contains tannin 28-40g, isofraxidin 0.02-0.1g. The extract can be used for preparing medicament for treating respiratory system infection diseases.
Description
Affiliated technical field
The invention belongs to field of medicaments, relate to the extract that derives from the Chinese crude drug Herba Pileae Scriptae and its purposes.
Background technology
Herba Pileae Scriptae is that Chloranthaceae Herba Pileae Scriptae (Sarcandra glabra (Thunb) Nakai) plant claims the aerial parts of Herba Sarcandrae again, the bibliographical information Herba Pileae Scriptae has clearing away heat and cooling blood, the effect of wind dispelling collateral dredging, the QINGRE XIAOYANNING JIAONANG of record has been gone on the market for many years in the 9th in China's medicine ministry standard Chinese traditional patent formulation preparation, and curative effect is sure, it is the pure Chinese medicinal preparation that the water extract with Herba Pileae Scriptae single medical material is prepared from, has heat-clearing and toxic substances removing, anti-inflammatory analgetic, the effect of relaxing muscles and tendons and activating QI and blood in the collateral.Be used for influenza, pharyngolaryngitis, pneumonia, bacillary dysentery, acute gastroenteritis, appendicitis, burn, skin infection abscess, cellulitis.QINGRE XIAOYANNING JIAONANG be the Herba Pileae Scriptae plant with water extraction after the capsule made of spissated dry crude product, so oral dose is bigger, therapeutic dose need be with every day 3 times, each 2～4, every dry extract 0.5g that contains the Herba Pileae Scriptae crude extract.In order to reduce taking dose, improve the curative effect of medicine, be necessary further to develop the medicinal plants Herba Pileae Scriptae, extract its effective medicinal part, guarantee the curative effect of medicine.
Summary of the invention
The objective of the invention is: development and use medicinal plants Herba Pileae Scriptae, adopt new technology to extract its effective medical active extract, remove the position invalid to main disease to be treated, reduce medication dose, improve activity, guarantee the curative effect of medicine; Another purpose is the medicine that the new activity extract of Herba Pileae Scriptae is prepared into the treatment respiratory infection diseases.
Technical scheme of the present invention is: the extract of Herba Pileae Scriptae is the aerial parts that adopts Chloranthaceae Herba Pileae Scriptae (Sarcandra glabra (Thunb) Nakai) plant, after putting forward the drying precipitate that ethanol precipitation obtains, water is activity extract, contain tannin 28～40 grams in the activity extract of its 100 grams, contain isofraxidin 0.02～0.1 gram.
Extraction process of the present invention is with the Chinese medicine water extraction of exsiccant Herba Pileae Scriptae arrangement back with routine, the water that obtains is carried filtrate and is condensed into extractum, the precipitate that obtains through the secondary precipitate with ethanol, dried dry product is an activity extract, can the directly encapsulated capsule of making behind crushing screening, or tabletting is made tablet etc.
Isofraxidin Determination on content method is according to 2000 editions the 180th page of described high effective liquid chromatography for measuring of Chinese Pharmacopoeia in the activity extract.
With tens of batches of content of measuring isofraxidin of the activity extract of Herba Pileae Scriptae provided by the present invention between 0.02～0.1% (percentage by weight).
The assay method of content of tannin is according to the mensuration of the 63rd page of tannin of Chinese Pharmacopoeia appendix of version in 2000 in the activity extract.
With tens of batches of content of measuring tannin of the activity extract of Herba Pileae Scriptae provided by the present invention between 28～40% (percentage by weights).
The purposes of Herba Pileae Scriptae extract provided by the present invention is the medicine of preparation treatment respiratory system infection disease, mainly is the medicine of preparation treatment flu, pharyngolaryngitis.
Respiratory system disease is common with infectivity, and primary infection causes that viral infection is particularly common owing to suck microorganisms such as virus, antibacterial, secondly is the specificity bacterial infection.
Confirm that with external and in vivo test product provided by the present invention has significant curative effect to respiratory infection diseases below, and prove that relatively the dosage that new product takes than original product is low, better efficacy with QINGRE XIAOYANNING JIAONANG.
One, in-vitro antibacterial test
Test specimen: 1, the dried cream powder of QINGRE XIAOYANNING, (hereinafter to be referred as original product) lot number 272004, content 10g crude drug/g dried cream powder.
2, the activity extract of Herba Pileae Scriptae extraction of the present invention, (hereinafter to be referred as new product), lot number 1116, content 31.75g crude drug/g dried cream powder.
3, acetic acid sprinkles mud pine sheet: lot number 010304, and the 5mg/ sheet, the permanent strong pharmaceutcal corporation, Ltd in Guangdong Jiangmen city produces.
4, Aspirin Enteric-coated Tablets: lot number 010301, the 50mg/ sheet, guilin pharmacy factory produces.
Strain: staphylococcus aureus (26003-21), escherichia coli (44103-5), bacillus pyocyaneus (10104-1), streptococcus pneumoniae (31003-16), beta hemolytic streptococcus (32210-17), hemophilus influenza (10105-32), all purchase in Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
Culture medium: broth bouillon, agar culture medium, serum broth dextrose culture-medium, defiber blood agar dextrose culture-medium.
Test method: adopt tube dilution method.
Result of the test:
| Bacterial classification inoculation bacterium amount new product (milligram crude drug/milliliter) original product (milligram crude drug/milliliter) (* 10 5CFU/ml)?MIC??????????MBC???????MIC???????????MBC |
| Staphylococcus aureus 2.0 31.3 31.3 31.3 36.4 Escherichia coli 2.0 416.7 500.0 250.0 500.0 Pseudomonas aeruginosas 1.6 125.0 236.1 250.0 250.0 Bacillus influenzaes 1.1 125.0 250.0 333.3 416.7 streptococcus pneumonias 1.0 125.0 125.0 250.0 250.0 hemolytic streptococcus 1.1 62.5 97.2 125.0 125.0 |
The result shows that new, original product all has antibacterial and bactericidal action to the common bacteria of respiratory tract infection, and new product is stronger 1～3 times than original product to the antibacterial activity of bacillus pyocyaneus, streptococcus pneumoniae, beta hemolytic streptococcus, hemophilus influenza; To staphylococcus aureus, antibacterial activity new, original product is suitable.
Two, antiinflammatory in the body, analgesic test
1, dish glue in diagonal angle causes the influence of rat paw edema
Result of the test:
*
| Group dosage number of animals (gram crude drug/kilogram) (gram extractum/kilogram) (only) | Cause scorching back different time paw swelling |
| 2h????????????4h???????????6h | |
| Model contrast distilled water distilled water 10 0.48 ± 0.10 0.52 ± 0.10 0.45 ± 0.09 | |
| Original product 12.0 1.20 10 0.33 ± 0.07 **?0.44±0.08???0.33±0.09 **??????????6.0???????0.60??????????9???????????????0.40±0.07????0.47±0.09???0.40±0.11 | |
| New product 12.0 0.38 10 0.30 ± 0.10 **?0.41±0.13???.32±0.13 *??????????6.0???????0.19??????????10??????????????0.34±0.10 **?0.40±0.08 *?0.33±0.09 *??????????3.0???????0.09??????????10??????????????0.29±0.11 **?0.42±0.12???0.29±0.12 ** | |
Annotate: compare with model control group,
*P＜0.05,
*P＜0.01
The result shows that new product 3.0,6.0,12.0 gram crude drug/kilogram dosage and original product 12.0 gram crude drug/kilogram dosage have obvious inhibitory action (p＜0.05 or 0.01 to the pedal swelling of the extremely scorching back of rat 2h, 6h; Wherein new product 6.0 gram crude drugs/kilogram group can obviously suppress the pedal swelling of rat to scorching back 4h, point out the antiinflammatory better effects if of this dosage.
2, xylol causes the influence of mice auricle swelling
| Group dosage number of animals (gram crude drug/kilogram) (gram extractum/kilogram) (only) | Auricle swelling degree (mg) |
| Model contrast distilled water distilled water 12 20.0 ± 3.5 | |
| Original product 16.8 1.68 13 15.7 ± 2.6 **??????????8.4?????????0.84????????9?????????????????20.3±4.9 | |
| New product 16.8 0.53 13 15.4 ± 2.2 **??????????8.4?????????0.26????????13????????????????15.9±1.6 **??????????4.2?????????0.13????????12????????????????19.5±1.7 ** | |
Annotate: compare with model control group,
*P＜0.05,
*P＜0.01
The result shows, compare with model control group, new product 8.4,16.8 gram crude drug/kilogram dosage and original product 16.8 gram crude drug/kilogram dosage xylol cause mice auricle swelling obvious inhibitory action (p＜0.01), and suppression ratio is respectively 20.5,23.0,21.5%.New product 8.4 gram crude drug/kilogram dosage and original product 8.4 gram crude drug/kilogram dosage comparison new products obviously are better than original product (p＜0.01).
3, antibacterial tests in the body
Test specimen: 1, the dried cream powder of QINGRE XIAOYANNING, (hereinafter to be referred as original product) lot number 272004, content 10g crude drug/g dried cream powder.
2, the activity extract of Herba Pileae Scriptae extraction of the present invention, (hereinafter to be referred as new product), lot number 1116, content 31.75g crude drug/g dried cream powder.
3, penicillin sodium salt: Huabei Pharmaceutic Co., Ltd produces, lot number: Y006309
4, gentamycin sulfate: bridge pharmaceutical factory in Guangzhou produces, lot number: 001202
Test method:
Get 540 of 18-22gNIH mices, male and female half and half are divided into 27 groups at random, gastric infusion, and once a day, continuous 2 days, matched group was irritated the water of stomach equivalent, positive drug penicillin, intramuscular administration of gentamycin.After the last administration 1 hour, each unit of group was by 1.0ml/ mouse peritoneal injection staphylococcus aureus, streptococcus pneumoniae, Escherichia coli bacteria liquid, gave behind the bacterium liquid strengthen being administered once in 1,6,12 hour, observed the death toll of each treated animal in 5 days.
Result of the test:
1, the preventive and therapeutic effect (n=20) to infecting in the staphylococcus aureus body
| Group dosage (g/kg) | Infect back mouse death rate (%) |
| 24h???????48h???????72h???????96h???????120h | |
| Distilled water-95 (19) 95 (19) 95 (19) 95 (19) 95 (19) | |
| 16.8 75, (15) 75, (15) 75, (15) 75, (15) 75, (15) new product 8.4 80, (16) 90, (18) 90, (18) 90, (18) 90, (18) 4.2 80, (16) 90, (18) 90, (18) 90, (18) 90, (18) | |
| ?????????16.8?????????????85(17)????90(18)????90(18)????90(18)????90(18) *Original product 8.4 90 (18) 100 (20) 100 (20) 100 (20) 100 (20) | |
Annotate: the numeral in the bracket is the animal dead number.
2, the preventive and therapeutic effect (n=20) to infecting in the streptococcus pneumoniae body
| Group dosage (g/Kg) | Infect back mouse death rate (%) |
| 24h???????48h????????72h???????96h???????120h | |
| Distilled water-95 (19) 100 (20) 100 (20) 100 (20) 100 (20) | |
| New product 16.8 90, (18) 95, (19) 95, (19) 95, (19) 95, (19) 8.4 95, (19) 100, (20) 100, (20) 100, (20) 100, (20) 4.2 100, (20) 100, (20) 100, (20) 100, (20) 100, (20) | |
| 16.8 80 (16) 85 (17) 85 (17) 85 (17) 85 (17) original products 8.4 85 (17) 100 (20) 100 (20) 100 (20) 100 (20) | |
3, the preventive and therapeutic effect (n=20) to infecting in the escherichia coli body
| Group dosage (g/Kg) | Infect back mouse death rate (%) |
| 24h???????48h???????72h???????96h???????120h | |
| Distilled water-95 (19) 95 (19) 95 (19) 95 (19) 95 (19) | |
| 16.8 85, (17) 90, (18) 90, (18) 90, (18) 90, (18) new product 8.4 85, (17) 90, (18) 90, (18) 90, (18) 90, (18) 4.2 85, (17) 95, (19) 95, (19) 95, (19) 95, (19) | |
| 16.8 85 (17) 90 (18) 90 (18) 90 (18) 90 (18) original products 8.4 95 (19) 100 (20) 100 (20) 100 (20) 100 (20) | |
The result shows: new product is strong to infecting the rejection ratio original product in the mice staphylococcus aureus body, suppresses strong slightly to infecting in the escherichia coli body.
Three, external anti-viral test
Test specimen: 1, original product, lot number 272004, content 10g crude drug/g dried cream powder.
2, the dried cream powder of new product, lot number 1116, content 31.75g crude drug/g dried cream powder.
3, contrast medicine: ZHONGSHENG WAN
Virus: respiratory syncytial virus (RSV), rhinovirus, 3 type grippe virus, 3 type parainfluenza viruses, I herpes simplex virus type.
Test method:
Get that new, original product is diluted to 40,30,20,10,4mg/ml, the Strain with the 200TCID50 of equivalent is mixed in 37 ℃ of effects 2 hours then, then respiratory syncytial virus is seeded in the Hep-2 cell, the I herpes simplex virus type is seeded in bhk cell, 3 type grippe virus is seeded in mdck cell, and 3 type parainfluenza viruses are seeded in the Vero cell, rhinovirus is seeded in diploid cell.3 type grippe virus is cultivated 48h for 33 ℃ and is made hemagglutination test, and 37 ℃ of cultivations of all the other viruses are done the blood cell adsorption test behind the 3 type parainfluenza virus 72h.
Result of the test:
1, medicine is to the vitro inhibition growth test result of respiratory syncytial virus
| Medicine name | Drug level (mg/ml) | Contrast |
| ??20????15????10????5????2 | Virocyte | |
| New product---± ++ +++-original product-± ++ +++-contrast medicine (ZHONGSHENG WAN)--± ++ ++++++- | ||
2, medicine is to the vitro inhibition growth test result of 3 type grippe virus
| Medicine name | Drug level (mg/ml) | Contrast |
| ??20????15????10????5???2 | Virocyte | |
| New product---± ++ +++-original product-± ++ +++-contrast medicine (ZHONGSHENG WAN)---+++ +++- | ||
1, medicine is to the vitro inhibition growth test result of I herpes simplex virus type
| Medicine name | Drug level (mg/m1) | Contrast |
| ??20????15????10????5??2 | Virocyte | |
| New product---± ++ +++-original product-± ++ +++-contrast medicine (ZHONGSHENG WAN)---± ++++++- | ||
4, medicine is to the vitro inhibition growth test result of 3 type parainfluenza viruses
| Medicine name | Drug level (mg/ml) | Contrast |
| ??20????15???10???5????2 | Virocyte | |
| New product-± ++ +++++++++-original product ++ +++++++++-contrast medicine (ZHONGSHENG WAN)-± ++ +++++ +++- | ||
5, medicine is to rhinoviral vitro inhibition growth test result
| Medicine name | Drug level (mg/ml) | Contrast |
| ?20????15????10????5???2 | Virocyte | |
| New product ++ ++ ++ +++++++++-original product ++ ++ ++ +++++++++-contrast medicine (ZHONGSHENG WAN) ++ ++ ++ +++++++++- | ||
Conclusion: the external minimum no cytotoxicity concentration of new product is 20mg/ml, and the minimum no cytotoxicity concentration of original product is 10mg/ml, has notable difference between the two, and the toxicity of prompting new product pair cell is lower than original product.Newly, the concentration of original product 5mg/ml can suppress respiratory syncytial virus, 3 type grippe virus and I herpes simplex virus type external, the concentration of new product 15mg/ml is external to suppress the growth of 3 type parainfluenza viruses, and original product fails to show inhibitory action, and the concentration of new, original product 20mg/ml all can not suppress the rhinovirus growth external.
Five, interior resisting virus test
1, to the protective effect of influenza virus infecting mouse
Medicine: original product dried cream powder, lot number 272004, content 10g crude drug/g dried cream powder.
The dried cream powder of new product, lot number 021001, content 31.75g crude drug/g dried cream powder.
Positive control drug: ribavirin, pharmaceutical factory, south China, Guangdong produces, lot number 030101.Influenza virus group: be FM
1The mice adapted strain.
Experimental result: anti-sense moistening and cleaning throat capsule is to the dead protective effect of influenza virus infecting mouse (x ± s)
The average survival of the dead protection of number of animals dosage infective dose death toll mortality rate sky prolongs gives birth to
Group
(n) g/kg LD
50Only (%) rate (%) is counted life rate %
Blank 10--0--＞14-
Negative control 10 1.00-0--＞14-
Virus control 15-4 12 80.0-9.73 ± 2.68-
QINGRE XIAOYANNING 15 1.00 48 53.3 26.7 10.93 ± 3.13 12.3
Ribavirin 15 0.013 41 6.1
*73.9 13.73 ± 1.03
*41.1
Low dosage 15 0.16 4 10 66.7 13.3 10.67 ± 2.74 9.7
Middle dosage 15 0.32 49 60.0 20.0 10.33 ± 3.24 6.2
High dose 15 0.64 49 60.0 20.0 10.80 ± 2.78 11.0
Annotate: compare with the virus control group,
*P＜0.05,
*P＜0.01.
The result shows that the low dosage of new product (0.16g/Kg) is suitable with the 1.0g/Kg dosage group of original product.
Six, product provided by the invention is to 437 example flu, pharyngolaryngitis clinical observation
Medicine: new product provided by the invention (anti-sense moistening and cleaning throat capsule, 0.32g/ grain)
Original product (QINGRE XIAOYANNING JIAONANG, 0.5g/ grain)
Administrated method: new product, oral, every day 3 times, each 2.
Original product, oral, every day 3 times, each 4.
1, to the clinical observation of 157 routine anemopyretic cold
Comparabilities detect and to show before two groups of treatments, two groups of ages, sex, the course of disease, main clinic symptoms, sign and picture of the tongues, pulse condition etc. relatively, difference there are no significant meaning.The principal element that prompting influences two groups of prognosis has harmony.
Western medicine diagnose is flu, and differential diagnosis in tcm belongs to wind heat and levies.
Curative effect relatively
(1) total effects relatively
Treatment group cure rate is 61.2%, and obvious effective rate 28.9%, effective percentage are 5.88%.The matched group cure rate is 44.4%, and obvious effective rate 25.0%, effective percentage are 13.9%.Two groups relatively, and difference has the significance meaning.
(2) treatment back clinical symptom disappearance rate relatively
The sweating of group nasal obstruction sneeze stream yellow thick nasal discharge aversion to cold headache pharyngalgia is not smooth thirsty uncomfortable in chest
Control original example several 191 107 109 70 98 85 39 107 13
Treat the example several 97 101 94 70 85 58 38 99 13 that disappears
Group disappearance rate % 81.51 94.39 86.24 100 86.73 68.24 97.44 92.52 100
To original example several 36 29 32 18 28 25 10 26 3
According to the example several 22 22 20 16 24 13 10 20 3 that disappears
Group disappearance rate % 61.11 75.86 62.5 88.89 85.71 52 100 76.92 100
The group whole body extremity coughs sticking expectorant yellow sputum amount heating of expectorant of coughing up phlegm is pharyngeal
The discomfort not well inflammation of aching
Control original example several 91 64 78 43 37 46 62 67 88
Treat the example several 81 54 44 32 29 35 41 54 51 that disappears
Group disappearance rate % 89.01 84.38 56.41 74.42 78.38 76.09 66.13 80.6 57.95
To original example several 24 16 23 11 10 10 17 24 26
According to the example several 15 996869 16 13 that disappears
Group disappearance rate % 62.5 56.25 39.13 54.55 80 60 52.94 88.67 50
2, to 280 routine acute pharyngitis patients' clinical observation
(1) shows through the comparability detection before the treatment, two groups of main clinic symptoms such as age, sex, pharyngeal pain, odynophagia, pharyngeal drying, pharyngeal burning sensation, hoarseness and pharyngeal inflammation, signs compare, difference there are no significant meaning, prompting influences the principal element tool harmony of two groups of prognosis.Two groups of Western medicine diagnoses are acute pharyngitis, and differential diagnosis in tcm is that wind heat is levied.
(2) curative effect relatively
Treatment group cure rate is 46.0%, and obvious effective rate 31.8%, effective percentage are 19.6%.The matched group cure rate is 29.3%, and obvious effective rate 34.1%, effective percentage are 31.7%.Two groups relatively, and difference has the significance meaning.
(2) treatment back clinical symptom disappearance rate relatively
The pharyngeal burning sensation hoarseness of the pharyngeal drying of the pharyngeal pain odynophagia of group
Control original example several 198 189 186 174 68
Treat the example several 127 142 129 138 61 that disappears
Group disappearance rate % 64.14 75.13 69.35 79.31 89.61
To original example several 81 76 74 69 37
According to the example several 39 47 40 50 34 that disappears
Group disappearance rate % 48.15 61.84 54.05 72.46 91.89
The thirsty inappetence extremities aching pain of the group aversion to cold pharyngeal inflammation antiadoncus that generates heat
Control original example several 71 164 98 91 73 197 109
Treat the example several 66 124 84 82 67 105 63 that disappears
Group disappearance rate % 92.96 75.61 85.71 90.11 91.78 53.30 57.89
To original example several 34 61 40 40 28 81 50
According to the example several 30 40 29 33 23 32 17 that disappears
Group disappearance rate % 88.24 65.57 72.50 82.50 82.14 39.51 34.0
Clinical effectiveness shows that product provided by the invention to flu, pharyngolaryngitis curative effect certainly.Be better than the heat clearing away QINGRE XIAOYANNING, dosage is lower than QINGRE XIAOYANNING.
Medicine with Herba Pileae Scriptae extract preparation provided by the invention, when being used for the treatment of respiratory system infection disease, the oral dose that uses, every day 3 times, each 2, every contains the 0.32g dried cream powder, than original product, the oral dose of QINGRE XIAOYANNING JIAONANG, every day 3 times, each 4, every contains the 0.5g dried cream powder and significantly reduces.
Below by embodiment technical scheme of the present invention is described.
The specific embodiment
Embodiment 1, get the aerial parts of usefulness Chloranthaceae Herba Pileae Scriptae (Sarcandra glabra (Thunb) Nakai) plant that produces in Guangxi, be the dry arrangement of Herba Pileae Scriptae 400Kg back water 3600Kg, boiled 2 hours, leaching filtrate, added the 3200Kg decocting in water again 2 hours, filter, merge filtrate twice, be condensed into 110.5Kg extractum, add ethanol under stirring, leave standstill, the centrifugal supernatant that gets adds ethanol again, the precipitate that obtains after leaving standstill, get activity extract 12.66Kg behind the vacuum drying, activity extract contains tannin 32.81% (g/g) after measured, isofraxidin 0.051% (g/g).
Embodiment 2, get the dry arrangement of the Herba Pileae Scriptae 400Kg that produces in Guangxi back water 3600Kg, boiled leaching filtrate 2 hours, add the 3200Kg decocting in water again 2 hours, and filtered, merge filtrate twice, be condensed into 113.0Kg extractum, add ethanol under stirring, leave standstill, the centrifugal supernatant that gets, add ethanol again, the precipitate that obtains after leaving standstill gets activity extract 12.90Kg behind the vacuum drying, activity extract contains tannin 35.20% (g/g) after measured, isofraxidin 0.034% (g/g).
Embodiment 3, get the dry arrangement of the Herba Pileae Scriptae 400Kg that produces in Guangxi back water 3600Kg, boiled leaching filtrate 2 hours, add the 3200Kg decocting in water again 2 hours, and filtered, merge filtrate twice, be condensed into 107.0Kg extractum, add ethanol under stirring, leave standstill, the centrifugal supernatant that gets, add ethanol again, the precipitate that obtains after leaving standstill gets activity extract 12.24Kg behind the vacuum drying, activity extract contains tannin 39.84% (g/g) after measured, isofraxidin 0.088% (g/g).
Embodiment 4, get the dry arrangement of the Herba Pileae Scriptae 400Kg that produces in Jiangxi back water 3600Kg, boiled leaching filtrate 2 hours, add the 3200Kg decocting in water again 2 hours, and filtered, merge filtrate twice, be condensed into 91.0Kg extractum, add ethanol under stirring, leave standstill, the centrifugal supernatant that gets, add ethanol again, the precipitate that obtains after leaving standstill gets activity extract 14.80Kg behind the vacuum drying, activity extract contains tannin 29.59% (g/g) after measured, isofraxidin 0.039% (g/g).
Embodiment 5, get the dry arrangement of the Herba Pileae Scriptae 400Kg that produces in Jiangxi back water 3600Kg, boiled leaching filtrate 2 hours, add the 3200Kg decocting in water again 2 hours, and filtered, merge filtrate twice, be condensed into 108.0Kg extractum, add ethanol under stirring, leave standstill, the centrifugal supernatant that gets, add ethanol again, the precipitate that obtains after leaving standstill gets activity extract 12.60Kg behind the vacuum drying, activity extract contains tannin 28.37% (g/g) after measured, isofraxidin 0.030% (g/g).
Embodiment 6, get the dry arrangement of the Herba Pileae Scriptae 400Kg that produces in Jiangxi back water 4000Kg, boiled leaching filtrate 2 hours, add 4000Kg again, decocting in water 2 hours filters, merge filtrate twice, be condensed into 91.5Kg extractum, add ethanol under stirring, leave standstill, the centrifugal supernatant that gets adds ethanol again, the precipitate that obtains after leaving standstill, get activity extract 16.0Kg behind the vacuum drying, activity extract contains tannin 30.21% (g/g) after measured, isofraxidin 0.024% (g/g).
Claims (3)
1, a kind of Herba Pileae Scriptae extract, it is characterized in that adopting the aerial parts of Chloranthaceae Herba Pileae Scriptae (Sarcandra glabra (Thunb) Nakai) plant, after putting forward the drying precipitate that ethanol precipitation obtains, water is activity extract, contain tannin 28～40 grams in the activity extract of its 100 grams, contain isofraxidin 0.02～0.1 gram.
2, the purposes of Herba Pileae Scriptae extract according to claim 1 is characterized in that being used to prepare the medicine for the treatment of respiratory infection diseases.
3, the purposes of Herba Pileae Scriptae extract according to claim 2 is characterized in that being used to prepare the medicine for the treatment of flu, pharyngolaryngitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410027691 CN1244332C (en) | 2004-06-18 | 2004-06-18 | Sarcandra extract and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410027691 CN1244332C (en) | 2004-06-18 | 2004-06-18 | Sarcandra extract and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593558A true CN1593558A (en) | 2005-03-16 |
| CN1244332C CN1244332C (en) | 2006-03-08 |
Family
ID=34663975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410027691 Active CN1244332C (en) | 2004-06-18 | 2004-06-18 | Sarcandra extract and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1244332C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101665479B (en) * | 2009-09-22 | 2012-05-16 | 三明华健生物工程有限公司 | Technology for synchronously extracting isofraxidin and flavonoids compounds from sarcandra glabra and applications thereof |
| CN105294410A (en) * | 2015-11-24 | 2016-02-03 | 湖南农业大学 | Pair of phenyl unsaturated triol isomer compounds separated and purified from chloranthus angustifolius, and preparation method and application thereof |
| CN106138156A (en) * | 2015-04-13 | 2016-11-23 | 阙锋 | A kind of relieving sore-throat by clearing away heat Chinese medicine preparation and preparation method thereof |
| CN112089737A (en) * | 2020-10-22 | 2020-12-18 | 贵州蔚源中药材产业开发有限公司 | Preparation technology of sarcandra glabra extract with throat clearing function |
-
2004
- 2004-06-18 CN CN 200410027691 patent/CN1244332C/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101665479B (en) * | 2009-09-22 | 2012-05-16 | 三明华健生物工程有限公司 | Technology for synchronously extracting isofraxidin and flavonoids compounds from sarcandra glabra and applications thereof |
| CN106138156A (en) * | 2015-04-13 | 2016-11-23 | 阙锋 | A kind of relieving sore-throat by clearing away heat Chinese medicine preparation and preparation method thereof |
| CN106138156B (en) * | 2015-04-13 | 2020-07-10 | 阙锋 | Traditional Chinese medicine preparation for clearing heat and relieving sore throat and preparation method thereof |
| CN105294410A (en) * | 2015-11-24 | 2016-02-03 | 湖南农业大学 | Pair of phenyl unsaturated triol isomer compounds separated and purified from chloranthus angustifolius, and preparation method and application thereof |
| CN105294410B (en) * | 2015-11-24 | 2016-08-17 | 湖南农业大学 | A pair phenyl unsaturation trihydroxylic alcohol isomeric compound isolated and purified from narrow leaf Chloranthus spicatus and its preparation method and application |
| CN112089737A (en) * | 2020-10-22 | 2020-12-18 | 贵州蔚源中药材产业开发有限公司 | Preparation technology of sarcandra glabra extract with throat clearing function |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1244332C (en) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1682842A (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
| CN1943675A (en) | Tibetan medicinal composition for expectorant, antitussive, antiasthmatic and its preparation method | |
| CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1857416A (en) | Chinese medicine composition with functions of expelling surficial evils and clearing away head and toxic materials and its preparing method and application | |
| CN1244332C (en) | Sarcandra extract and its application | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN108586626B (en) | Preparation method and application of tetrastigma hemsleyanum Diels et Gilg oligosaccharide | |
| CN1857399A (en) | Composition for preventing and treating stomatosis and its preparing method | |
| CN1698691A (en) | Medicine for treating cough due to lung heat/toxin and preparation method thereof | |
| CN100542578C (en) | The extract and the extracting method of the combined traditional Chinese medicine material of treatment respiratory system disease | |
| CN101077380A (en) | Antivirus medicinal composition and preparation method thereof | |
| CN100335044C (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1803155A (en) | Medicine for curing rhinitis | |
| CN1799603A (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN100344319C (en) | Chinese medicine composition for treating urogenital system disease and its preparing method and use | |
| CN1876151A (en) | A pharmaceutical composition for treating cold, its preparation method and use | |
| CN1593564A (en) | Medicine for treating cold and its preparing process | |
| CN1216609C (en) | Scutellaria root extract nose preparation | |
| CN1709489A (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN1299707C (en) | Yinhuang oral liquor and its producing process | |
| CN1895458A (en) | Compound Chinese-medicinal extract for treating gynaopathy and its preparation | |
| CN1843419A (en) | Externally used traditional Chinese medicine composition for treating dermatosis | |
| CN1297260C (en) | Fatty acyl acetaldehyde powder projection and its preparing method | |
| CN1176939C (en) | Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: GUANGZHOU BAIYUNSHAN JINGXIUTANG PHARMACEUTICAL CO Free format text: FORMER NAME: JINGXIUTANG (PHARMACEUTICAL) CO., LTD., GUANGZHOU;JINGXIUTANG (PHARMACEUTICAL) CO., LTD., GUANGZHOU |
|
| CP03 | Change of name, title or address |
Address after: 510130 No. 179 Renmin South Road, Guangzhou, Guangdong, Liwan District Patentee after: Guangzhou Baiyunshan Jingxiutang Pharmaceutical Company Limited Address before: 510130 No. 179 Renmin South Road, Guangdong, Guangzhou Patentee before: Jingxiutang (Pharmacy) Co., Ltd., Guangzhou |